Skip to content
Disclosery

Ghost Tree Capital, LLC

Follow

13F filer, CIK 1595851, NEW YORK, NY

Ghost Tree Capital, LLC reported $319,338,992 across 63 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-14. Its ten largest share positions make up 40.75% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-24-001501

Period
2024-06-30
Reported value
$319M
Holdings
63
Top 10 weight
40.75%
New
15
Sold out
24

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ASNDnew+86,721$11.8M
CATXnew+925,000$9.22M
BHVNadded+205,000$7.12M
RZLTnew+1,421,501$6.11M
CGONadded+185,000$5.84M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SRPTreduced-70,000-$11.1M
ALNYreduced-37,500-$9.11M
PERSPECTIVE THERAPEUTICS INCexited-6,000,000-$7.14M
AEROVATE THERAPEUTICS INCexited-225,000-$6.65M
TGTXreduced-325,000-$5.78M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0001420506-24-001501, largest first. % of portfolio is the value over $287,351,742, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 275,000 shares; 2024Q1: 285,000 shares; 2024Q2: 490,000 shares 490,000$17M5.92%+205,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 195,000 shares; 2023Q2: 330,000 shares; 2023Q3: 330,000 shares; 2023Q4: 80,000 shares; 2024Q1: 300,000 shares; 2024Q2: 300,000 shares 300,000$13.2M4.59%0Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 112,385 shares; 2024Q1: 200,000 shares; 2024Q2: 300,000 shares 300,000$12.2M4.26%+100,000Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 235,000 shares; 2023Q1: 225,000 shares; 2023Q2: 110,000 shares; 2023Q3: 110,000 shares; 2023Q4: 165,000 shares; 2024Q1: 210,000 shares; 2024Q2: 150,000 shares 150,000$12.1M4.2%-60,000Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 130,000 shares; 2023Q1: 110,000 shares; 2023Q2: 100,000 shares; 2023Q3: 85,000 shares; 2023Q4: 20,000 shares; 2024Q1: not reported; 2024Q2: 86,721 shares 86,721$11.8M4.12%newTimeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 160,000 shares; 2023Q1: 225,000 shares; 2023Q2: 280,000 shares; 2023Q3: 140,000 shares; 2023Q4: 70,000 shares; 2024Q1: 95,000 shares; 2024Q2: 150,000 shares 150,000$11.3M3.94%+55,000Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 101,443 shares; 2023Q4: 65,000 shares; 2024Q1: 200,000 shares; 2024Q2: 240,000 shares 240,000$10.7M3.74%+40,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 64,000 shares; 2023Q3: 64,000 shares; 2023Q4: 600,000 shares; 2024Q1: 1,300,000 shares; 2024Q2: 1,000,000 shares 1,000,000$10.6M3.68%-300,000Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 925,000 shares 925,000$9.22M3.21%newTimeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,100,000 shares; 2023Q2: 825,000 shares; 2023Q3: 1,000,000 shares; 2023Q4: 250,000 shares; 2024Q1: 825,000 shares; 2024Q2: 500,000 shares 500,000$8.89M3.1%-325,000Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 55,000 shares; 2023Q1: 60,000 shares; 2023Q2: 85,000 shares; 2023Q3: 40,000 shares; 2023Q4: 100,000 shares; 2024Q1: 125,000 shares; 2024Q2: 55,000 shares 55,000$8.69M3.02%-70,000Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 75,000 shares; 2024Q2: 260,000 shares 260,000$8.21M2.86%+185,000Timeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 56,941 shares; 2024Q2: 175,000 shares 175,000$7.92M2.76%+118,059Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 165,000 shares; 2023Q1: 175,000 shares; 2023Q2: 240,000 shares; 2023Q3: 275,000 shares; 2023Q4: 300,000 shares; 2024Q1: 625,000 shares; 2024Q2: 587,708 shares 587,708$7.65M2.66%-37,292Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 150,000 shares; 2023Q1: 325,000 shares; 2023Q2: 350,000 shares; 2023Q3: 200,000 shares; 2023Q4: not reported; 2024Q1: 150,000 shares; 2024Q2: 350,000 shares 350,000$7.19M2.5%+200,000Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 130,000 shares; 2023Q4: not reported; 2024Q1: 125,000 shares; 2024Q2: 260,000 shares 260,000$6.86M2.39%+135,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 80,000 shares; 2023Q1: 80,000 shares; 2023Q2: 150,000 shares; 2023Q3: 400,000 shares; 2023Q4: 300,000 shares; 2024Q1: 300,000 shares; 2024Q2: 235,000 shares 235,000$6.39M2.22%-65,000Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 154,250 shares; 2023Q3: 395,000 shares; 2023Q4: 385,241 shares; 2024Q1: 485,000 shares; 2024Q2: 600,000 shares 600,000$6.18M2.15%+115,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 1,421,501 shares 1,421,501$6.11M2.13%newTimeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 200,000 shares; 2024Q2: 550,000 shares 550,000$5.95M2.07%+350,000Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 100,000 shares; 2024Q2: 250,237 shares 250,237$5.88M2.05%+150,237Timeline
ALNYALNYLAM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 27,500 shares; 2024Q1: 60,000 shares; 2024Q2: 22,500 shares 22,500$5.47M1.9%-37,500Timeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 164,620 shares; 2023Q2: 180,000 shares; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 130,000 shares; 2024Q2: 135,000 shares 135,000$5.18M1.8%+5,000Timeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 600,000 shares; 2023Q2: 650,000 shares; 2023Q3: 225,000 shares; 2023Q4: not reported; 2024Q1: 73,002 shares; 2024Q2: 95,000 shares 95,000$5.04M1.75%+21,998Timeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 125,000 shares; 2024Q2: 117,388 shares 117,388$4.82M1.68%-7,612Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 150,000 shares; 2024Q2: 65,000 shares 65,000$4.36M1.52%-85,000Timeline
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 20,000 shares; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 72,761 shares; 2024Q2: 40,000 shares 40,000$4.31M1.5%-32,761
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 750,000 shares; 2024Q1: 1,600,000 shares; 2024Q2: 1,050,876 shares 1,050,876$4.24M1.47%-549,124Timeline
TNYATENAYA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 775,000 shares; 2024Q2: 1,350,000 shares 1,350,000$4.18M1.46%+575,000Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 10,865 shares; 2023Q3: not reported; 2023Q4: 400,000 shares; 2024Q1: 650,000 shares; 2024Q2: 450,000 shares 450,000$4.05M1.41%-200,000Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 200,000 shares; 2024Q2: 420,331 shares 420,331$3.96M1.38%+220,331Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 80,000 shares; 2023Q4: 50,000 shares; 2024Q1: 225,000 shares; 2024Q2: 225,000 shares 225,000$3.66M1.27%0Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 25,000 shares; 2023Q2: 42,000 shares; 2023Q3: 75,000 shares; 2023Q4: 125,000 shares; 2024Q1: 175,000 shares; 2024Q2: 140,000 shares 140,000$3.55M1.23%-35,000Timeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 100,000 shares 100,000$3.39M1.18%newTimeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 1,150,000 shares 1,150,000$3.36M1.17%newTimeline
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP IIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 300,000 shares; 2024Q2: 300,000 shares 300,000$3.07M1.07%0
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 1,325,000 shares; 2023Q4: 2,100,000 shares; 2024Q1: 950,000 shares; 2024Q2: 1,250,000 shares 1,250,000$2.8M0.97%+300,000Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 150,000 shares; 2024Q1: 375,000 shares; 2024Q2: 370,899 shares 370,899$2.77M0.97%-4,101Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 25,000 shares; 2024Q2: 70,000 shares 70,000$2.55M0.89%+45,000Timeline
JANXJANUX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 50,000 shares 50,000$2.09M0.73%newTimeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 59,250 shares; 2024Q1: 40,000 shares; 2024Q2: 75,000 shares 75,000$2M0.69%+35,000Timeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 120,000 shares; 2024Q2: 170,000 shares 170,000$1.99M0.69%+50,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 90,000 shares; 2023Q4: 10,000 shares; 2024Q1: 20,000 shares; 2024Q2: 33,200 shares 33,200$1.8M0.63%+13,200Timeline
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 250,000 shares; 2024Q2: 600,000 shares 600,000$1.62M0.56%+350,000
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 20,000 shares; 2023Q3: 80,000 shares; 2023Q4: 50,000 shares; 2024Q1: 14,000 shares; 2024Q2: 8,500 shares 8,500$1.56M0.54%-5,500Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 310,000 shares 310,000$1.52M0.53%newTimeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 900,000 shares 900,000$1.49M0.52%newTimeline
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 600,000 shares; 2024Q2: 800,000 shares 800,000$1.25M0.43%+200,000Timeline
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 200,000 shares 200,000$998K0.35%newTimeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 35,000 shares; 2024Q2: 35,000 shares 35,000$910K0.32%0Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 225,000 shares; 2024Q2: 225,000 shares 225,000$770K0.27%0Timeline
INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 10,000 shares 10,000$685K0.24%new
MGNXMACROGENICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 150,000 shares 150,000$638K0.22%newTimeline
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 280,981 shares; 2023Q3: 705,881 shares; 2023Q4: 725,000 shares; 2024Q1: 675,000 shares; 2024Q2: 375,000 shares 375,000$608K0.21%-300,000Timeline
PTCTPTC THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 16,675 shares; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 19,000 shares 19,000$581K0.2%newTimeline
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 250,000 shares; 2023Q2: 525,000 shares; 2023Q3: 350,000 shares; 2023Q4: 375,000 shares; 2024Q1: 450,000 shares; 2024Q2: 225,000 shares 225,000$578K0.2%-225,000
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 25,000 shares; 2024Q2: 25,000 shares 25,000$560K0.19%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 219,331 shares; 2024Q2: 219,331 shares 219,331$472K0.16%0Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 600,000 shares; 2024Q2: 300,000 shares 300,000$366K0.13%-300,000Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ALNYALNYLAM PHARMACEUTICALS INC Stockput68,400$16.6Mnew
INSMINSMED INC Stockcall200,000$13.4Mnew
ANNXANNEXON INC COMcall214,500$1.05Mnew
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC COMcall300,000$915K0

Sold out in Q2 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
XBISPDR SERIES TRUST250,000$23.7Mput
PERSPECTIVE THERAPEUTICS INCPERSPECTIVE THERAPEUTICS INC6,000,000$7.14Mshares
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INC225,000$6.65Mshares
VKTXVIKING THERAPEUTICS INC80,000$6.56Mcall
CYTKCYTOKINETICS INC75,000$5.26Mcall
IMVTIMMUNOVANT INC150,000$4.85Mcall
ACADACADIA PHARMACEUTICALS INC200,000$3.7Mcall
INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INC50,000$3.46Mcall
GPCRSTRUCTURE THERAPEUTICS INC75,000$3.21Mshares
COGTCOGENT BIOSCIENCES INC450,000$3.02Mshares
AQSTAQUESTIVE THERAPEUTICS INC702,941$2.99Mshares
DECIPHERA PHARMACEUTICALS INDECIPHERA PHARMACEUTICALS IN176,513$2.78Mshares
GERNGERON CORP800,000$2.64Mshares
MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC285,000$2.58Mshares
ALTALTIMMUNE INC250,000$2.54Mshares
KALVKALVISTA PHARMACEUTICALS INC200,000$2.37Mshares
NTRANATERA INC25,000$2.29Mshares
PTGXPROTAGONIST THERAPEUTICS INC75,000$2.17Mshares
EYPTEYEPOINT INC90,000$1.86Mshares
MDGLMADRIGAL PHARMACEUTICALS INC6,500$1.74Mshares
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INC115,000$1.62Mshares
LRMRLARIMAR THERAPEUTICS INC210,603$1.6Mshares
RAREULTRAGENYX PHARMACEUTICAL IN20,000$934Kshares
QUREUNIQURE NV165,000$858Kshares

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-24-001501 base2024-08-14acceptance time not in the bulk data set